Stoke Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$12.35(as of Jul 17, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Stoke Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$12.35
Ticker SymbolSTOK
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees128
CountyUSA
Market Cap$641.5M
EBIDTA40.3M
10-Day Moving Average11.84
P/E Ratio14.06
20-Day Moving Average11.73
Forward P/E Ratio0.00
50-Day Moving Average10.72
Earnings per Share0.82
200-Day Moving Average10.51
Profit Margin71.19%
RSI59.31
Shares Outstanding54.6M
ATR0.50
52-Week High16.15
Volume678,033
52-Week Low5.35
Most Recent Support Level11.66
Book Value350.1M
Most Recent Resistance Level12.11
P/B Ratio2.02
Upper Keltner12.84
P/S Ratio3.70
Lower Keltner10.61
Debt-to-Equity Ratio12.84
Next Earnings Date08/11/2025
Cash Surplus230.1M
Next Ex-Dividend DateUnknown

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stoke Therapeutics Inc In Our Stock Scanner

example chart graphic
Date: Jul 17, 2025Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Date: Jul 17, 2025Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 17, 2025Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 17, 2025Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 17, 2025Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 17, 2025Scan Name: Falling WedgeScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.